MVST Shareholder Alert: September 21, 2026 Lead Plaintiff Deadline in Microvast Holdings, Inc. Securities Class Action

Microvast shares fell $0.79, or 34.2%, to $1.52 on March 17, 2026 after Q4 2025 revenue of $96.5 million missed the $136.4 million consensus estimate, gross margin reached just 1.0%, and the company recorded a $32.5 million ESS inventory impairment. A securities class action alleges Microvast overstated gross-margin targets and the timing of its Huzhou Phase 3.2 expansion while failing to adequately disclose customer rollout delays and inventory risks. The proposed class covers investors who bought MVST securities between April 1, 2025 and March 16, 2026, with a September 21, 2026 lead-plaintiff deadline.

Analysis

The legal filing itself is not a fresh fundamental catalyst; the investable issue is that the alleged disclosure failures point to a lower-confidence earnings base and potentially recurring working-capital leakage. A near-zero gross-margin outcome combined with impaired specialized inventory suggests that the problem is not merely delayed revenue recognition: it raises the probability of unfavorable pricing, product/customer concentration, or obsolete configuration risk. That should keep the equity valued on liquidity runway and evidence of order conversion rather than on a normalized-margin recovery multiple over the next 1-3 quarters.

The key near-term catalyst is the next earnings release: investors need proof that inventory reserves have been fully taken, backlog has converted into revenue, and gross margin can recover without another revenue reset. A second impairment, incremental capacity delay, or cash-burn acceleration would materially increase financing/dilution risk within 6-18 months; conversely, a clean quarter with positive gross-margin progression could drive a sharp short-covering rally given the already-dislocated share price. Consensus may overemphasize litigation headlines: securities cases commonly have limited direct P&L impact, but they can constrain management attention and make equity financing more expensive precisely when operational execution requires capital.

Key Decisions for Investors

• Maintain an underweight/no-add stance in MVST through the next earnings release; require evidence of sequential gross-margin recovery, no further inventory reserve, and disclosed cash runway before reassessing a long.
• For mandates able to short small-cap equities, consider a tactical MVST short only after a failed post-litigation bounce and subject to confirmed borrow availability; target a 20-30% downside over 1-3 months if guidance or cash burn deteriorates, with a hard risk limit on a close above the post-earnings recovery high because low-float short squeezes are the primary risk.
• Do not buy MVST puts without verifying open interest and implied volatility. If options are illiquid or volatility already embeds another adverse disclosure, use an equity-risk alert rather than paying elevated premium.
• Set an earnings watch item: cover or avoid the bearish thesis if management demonstrates sustained double-digit gross margin, confirms inventory normalization, and provides a credible funded path through planned production expansion; those datapoints would shift the narrative from balance-sheet risk to operational recovery.